These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22226627)

  • 1. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Melosky B; Peacock S
    J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib for the treatment of relapsed non-small cell lung cancer.
    McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
    Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
    J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
    Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M
    Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
    Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
    Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic review of erlotinib in non-small-cell lung cancer.
    Yeung K; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA; Rudakova AV
    Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
    Nadler E; Forsyth M; Satram-Hoang S; Reyes C
    J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
    Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
    Boyer M; Horwood K; Pavlakis N; De Souza P; Millward M; Stein B; Johnston M; Abell F; Rischin D
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
    Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
    Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
    Tiseo M; Gridelli C; Cascinu S; Crinò L; Piantedosi FV; Grossi F; Brandes AA; Labianca R; Siena S; Amoroso D; Belvedere O; Valentino B; Bearz A; Venturino P; Ardizzoni A
    Lung Cancer; 2009 May; 64(2):199-206. PubMed ID: 18951651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
    Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
    J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.